Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1129)	4/17/2002 5:06:17 PM
From: keokalani'nui	Respond to of 2243

Yes, Merck's most advanced HIV vaccine is in part produced on Perc6--and Merck negotiated some exclusive options in other infectious disease areas. After R&D feasibility, the line was recently licensed for Japanese Encephaliitis vaccine by one of two companies with commercial JE products. No doubt there are flu and ??? vaccine candidates coming. The line is now licensed for Mab production by small Beligian BT. JnJ just accepted into commercial development an anti-cancer Mab. Oh, that's enough for now. As I said, there is a little more I'd like to see before risking T/FIF's performance metrics.